| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
|
5,336 |
3,730 |
$500K |
| 99284 |
|
1,357 |
966 |
$188K |
| 99282 |
|
2,274 |
1,679 |
$138K |
| 71046 |
|
1,477 |
1,164 |
$56K |
| 99285 |
|
244 |
188 |
$50K |
| 87502 |
|
1,303 |
942 |
$48K |
| 87635 |
|
1,112 |
958 |
$46K |
| 96374 |
|
540 |
431 |
$35K |
| 80053 |
|
4,668 |
3,606 |
$32K |
| 85025 |
|
5,640 |
4,281 |
$26K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
1,265 |
919 |
$25K |
| 87634 |
|
760 |
560 |
$22K |
| 97110 |
|
579 |
121 |
$22K |
| 96372 |
|
646 |
518 |
$21K |
| 70450 |
|
147 |
121 |
$18K |
| 93005 |
|
877 |
645 |
$15K |
| 87426 |
|
723 |
618 |
$14K |
| 36415 |
|
5,794 |
4,401 |
$11K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
45 |
44 |
$10K |
| 87651 |
|
500 |
367 |
$8K |
| 84443 |
|
703 |
585 |
$8K |
| 87880 |
|
563 |
511 |
$7K |
| 80307 |
|
207 |
151 |
$7K |
| 80061 |
|
735 |
600 |
$6K |
| 87804 |
|
371 |
283 |
$4K |
| 83036 |
|
683 |
559 |
$4K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
112 |
81 |
$4K |
| 74177 |
|
36 |
26 |
$4K |
| 81000 |
|
1,026 |
816 |
$3K |
| 99281 |
|
74 |
54 |
$3K |
| 87275 |
|
243 |
211 |
$3K |
| 87276 |
|
213 |
187 |
$3K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
12 |
12 |
$2K |
| 96375 |
|
141 |
116 |
$2K |
| 71045 |
|
76 |
55 |
$2K |
| 81001 |
|
1,287 |
948 |
$2K |
| 80305 |
|
206 |
162 |
$2K |
| 81025 |
|
315 |
221 |
$1K |
| 84484 |
|
296 |
167 |
$1K |
| 83880 |
|
30 |
27 |
$839.72 |
| 74018 |
|
23 |
12 |
$784.82 |
| 73030 |
|
12 |
12 |
$543.28 |
| 0012A |
|
16 |
16 |
$408.50 |
| 81002 |
|
173 |
149 |
$391.19 |
| 96361 |
|
19 |
15 |
$365.38 |
| 0031A |
|
18 |
13 |
$341.29 |
| 99454 |
|
47 |
34 |
$301.09 |
| 0011A |
|
17 |
17 |
$239.00 |
| 82553 |
|
37 |
14 |
$212.09 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
257 |
194 |
$92.81 |
| 36592 |
|
55 |
37 |
$79.54 |
| 87086 |
|
12 |
12 |
$59.28 |
| 83690 |
|
19 |
17 |
$48.09 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
108 |
82 |
$16.13 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
14 |
12 |
$4.20 |
| 99458 |
|
42 |
29 |
$0.00 |
| 91301 |
|
13 |
13 |
$0.00 |
| 99457 |
|
42 |
29 |
$0.00 |
| S9110 |
Telemonitoring of patient in their home, including all necessary equipment; computer system, connections, and software; maintenance; patient education and support; per month |
457 |
33 |
$0.00 |